8-K: Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Cartesian Therapeutics announces its full year 2024 financial results, highlighting progress in its clinical trials and a strong cash position to support operations into mid-2027.

Summary

• Cartesian Therapeutics reported its financial results for the year ended December 31, 2024.
• The company's Phase 3 AURORA trial of Descartes-08 in myasthenia gravis is on track to commence in the first half of 2025.
• Phase 2 trial of Descartes-08 in systemic lupus erythematosus is ongoing, with data expected in the second half of 2025.
• A Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications is expected to begin in the second half of 2025.
• Dosing is underway in the first-in-human Phase 1 trial of Descartes-15.
• The company had approximately $214.3 million in cash, cash equivalents, and restricted cash as of December 31, 2024, which is expected to fund operations into mid-2027.
• Research and development expenses were $45.1 million for the year ended December 31, 2024, compared to $71.3 million for the year ended December 31, 2023.
• Net loss was $(77.4) million, or $(4.48) net loss per share (basic), for the year ended December 31, 2024, compared to net loss of $(219.7) million for the year ended December 31, 2023.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with progress in clinical trials, a strong cash position, and a decrease in net loss. However, the company is still operating at a loss, which tempers the overall sentiment.

Positives

• The company has a strong cash position of $214.3 million, expected to fund operations into mid-2027.
• The Phase 3 AURORA trial of Descartes-08 in myasthenia gravis is on track to commence in the first half of 2025.
• Positive results from the Phase 2b trial of Descartes-08 in myasthenia gravis showed durable improvements over 12 months.
• The FDA has agreed to the design of the Phase 3 AURORA trial under a Special Protocol Assessment (SPA).
• Emily English was promoted to Chief Operations Officer.

Negatives

• The company reported a net loss of $(77.4) million for the year ended December 31, 2024.
• The company has a history of recurring losses from operations and negative cash flows.

Risks

• The company's future performance is subject to the uncertainties inherent in clinical trials, including uncertain outcomes and potential delays.
• The company relies on third parties to conduct its clinical trials.
• The company's success depends on its ability to protect its proprietary technology and intellectual property.
• The company's financial results are subject to risks related to geopolitical conflicts and pandemics.

Future Outlook

The company expects its cash balance to support operations into mid-2027, including the completion of the Phase 3 AURORA trial. They anticipate preliminary data from the Phase 2 SLE trial and initiation of the Phase 2 pediatric basket trial in the second half of 2025.

Management Comments

• Following a year marked by tremendous progress, we remain committed to advancing our pipeline of mRNA cell therapies designed to be dosed in the convenient outpatient setting, without the need for preconditioning chemotherapy, said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian.
• Notably, we remain on track to commence our planned Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG) in the first half of this year.
• Supported by positive results from our Phase 2b trial demonstrating deep and durable improvements for Descartes-08-treated participants, along with our Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA), we are confident that we have a clear path toward potential approval of this promising new therapy.
• Beyond MG, we remain on track to report preliminary data from our ongoing Phase 2 open-label trial of Descartes-08 in patients with systemic lupus erythematosus (SLE) and expect to initiate our Phase 2 pediatric basket trial of Descartes-08 in select autoimmune diseases in the second half of this year.
• With these anticipated milestones, along with our strong balance sheet, we believe we are well-positioned to deliver on our mission to expand the reach of cell therapy to autoimmunity.

Industry Context

Cartesian Therapeutics is focused on mRNA cell therapy for autoimmune diseases, a field with significant unmet medical needs. Their approach of outpatient administration without preconditioning chemotherapy differentiates them from traditional CAR-T therapies, potentially expanding the reach of cell therapy to a broader patient population.

Comparison to Industry Standards

• Cartesian's approach of using mRNA CAR-T therapy without preconditioning chemotherapy is a notable differentiator compared to traditional DNA-based CAR-T therapies like Novartis's Kymriah and Gilead's Yescarta, which require lymphodepleting chemotherapy.
• The company's focus on autoimmune diseases sets it apart from many CAR-T companies that primarily target oncology, such as Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead).
• The $214.3 million cash position provides a runway into mid-2027, which is a strong indicator of financial stability compared to other biotech companies in the clinical stage.

Management Changes

Stakeholder Impact

• Shareholders: The progress in clinical trials and strong cash position are positive for shareholders.
• Employees: The promotion of Emily English and continued operations are positive for employees.
• Patients: The development of new therapies for autoimmune diseases has the potential to improve patient outcomes.

Next Steps

• Commence Phase 3 AURORA trial of Descartes-08 in myasthenia gravis in the first half of 2025.
• Report preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus in the second half of 2025.
• Initiate Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications in the second half of 2025.
• Continue dosing in Phase 1 trial of Descartes-15.

Key Dates